Covance Launches Pharmacokinetic Service Line

Aug. 5, 2007 - PRLog -- Covance (Madison, Wisconsin) has begun offering pharmacokinetic studies using B-Clear, described as the only in-vitro method to predict in-vivo liver disposition.  The company licensed B-Clear from Qualyst (Raleigh, North Carolina), a specialist in ADMET (absorption, distribution, metabolism, excretion and toxicology) technology, in October 2006.  Terms of the deal were not disclosed.

B-Clear is a sandwich-cultured hepatocyte system that predicts hepatobiliary disposition, including hepatic uptake, hepatic accumulation, biliary clearance and drug transport.  It can be used as a screen for lead optimisation during drug discovery and to address drug transport questions during development.  It is said to enable better prediction of bioavailability, pharmacokinetics, species-specific drug dosing and candidate selection.

Covance will initially offer B-Clear-HU (primary human) and B-Clear-RT (primary rat) hepatocytes for hepatobiliary disposition and hepatic transport studies.  Services using non-human primate, canine and mouse hepatocytes are expected to become available in late 2007. Submitted by  www.jobs4dd.com E-mail : info@jobs4dd.com

# # #

About Jobs4 Drug Development Ltd:
Founded and developed under the Jobs4 Group and BioPharm Knowledge Publishing Ltd – Jobs4Drug Development will be launching an online recruitment service specialising in finding jobs for the clinical research, biopharm and drug development sectors. Additional information is available at www.jobs4dd.com
For more information please contact:

Website: www.jobs4dd.com